Poxel : Corporate Presentation

Corporate Presentation

March 2021

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward- looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward- looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business. As of the date of this presentation, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company's ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs and partnered programs. The Company will continue to actively monitor the situation.

2

Poxel's Mission and Vision

To discover, develop and commercialize innovative therapies for patients suffering from serious chronic diseases with underlying metabolic pathophysiology

acetyl CoA

METABOLIC	INFLAMMATION
DISORDERS
(cellular energy	TISSUE
homeostasis
imbalances)	DEGENERATION
& CELL DEATH
	apoptosis,
	necrosis

3

Three Pillars of Poxel's Strategy

First-in-Class Programs Leading to Key Value Inflection Points

		Unique platforms
Partnered in Asia1 with diabetes	Oral First-in-	AMPK	D-TZD	Pipeline
Platform	Platform	expansion	External
market leader in Japan	Class Phase 2			into new
Sumitomo Dainippon Pharma	Programs			indications	Opportunities

Imeglimin	PXL770	Next
		generation
	PXL065	compounds

Expected approval in 20212	Phase 2 biopsy data for both	New clinical programs in
triggering milestones	programs in 2022-2023	next 12-24 months
Phase 3 ready partnership	Combination potential	Further strengthening
opportunity in US/EUR		product pipeline

1. Including: Japan, China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos. 2. Sumitomo fiscal year April-March.

4

Poxel Platforms and Molecules Target Key Nodes that Regulate Cellular Energy Homeostasis

Multiple Entry Points Available to Intervene in Metabolic Diseases

NASH Other

AMP-activated Protein Kinase (AMPK)

Activator Platform

cellular energy sensor :

reduces liver fat, increases insulin sensitivity, decreases inflammation

NASH Other

Deuterium-Stabilized TZD* Platform non-genomic pathway modulators of mitochondrial pyruvate carrier -

• key fuel gate-keeper : promotes fat utilization, increases insulin
  sensitivity, decreases inflammation

T2D

Imeglimin- modulates mitochondrial respiratory chain (MRC), cell's energy producing machine: improved islet β- cell function; insulin sensitization; cardiorenal benefits; several other disease opportunities

AMPK

MPC

Pyruvate

Activates	Inhibits
catabolic	inflammation
pathways	apoptosis	T
	Inhibits anabolic
	pathways

* Thiazolidinediones (glitazones) - operate via PPARγ and non-genomic pathways including MPC (mitochondrial pyruvate carrier).

5

Acetyl
Co-A	TCA	ATP
	cycle
		NADH
		FADH2

MRC

MITOCHONDRIA